A recent prospective clinical study has shown that antiviral therapy with HIV protease inhibitors (PIs) is associated with a syndrome of peripheral fat wasting (lipodystrophy) and disordered glucose and lipid metabolism (Carr et al. 1999). We have studied the effects of indinavir and saquinavir, two HIV protease inhibitors, on cultured primary human preadipocytes and report that these compounds inhibit their differentiation. However, we find that these agents do not inhibit either transcriptional activation or adipocyte P2 gene induction by the PPARgamma/RXR nuclear receptor heterodimer. Together, our findings suggest that impaired adipogenesis is the basis of PI-associated lipodystrophy, but that this occurs via a PPARgamma/RXR-independent mechanism.

This article has been cited by other articles:

				J. A. Perez-Molina, P. Domingo, E. Martinez, and S. Moreno The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy J. Antimicrob. Chemother., August 1, 2008; 62(2): 234 - 245. [Abstract] [Full Text] [PDF]

				M. Prot, L. Heripret, N. Cardot-Leccia, C. Perrin, M. Aouadi, T. Lavrut, R. Garraffo, P. Dellamonica, J. Durant, Y. Le Marchand-Brustel, et al. Long-Term Treatment with Lopinavir-Ritonavir Induces a Reduction in Peripheral Adipose Depots in Mice Antimicrob. Agents Chemother., December 1, 2006; 50(12): 3998 - 4004. [Abstract] [Full Text] [PDF]

				K. E. Hadri, M. Glorian, C. Monsempes, M.-N. Dieudonne, R. Pecquery, Y. Giudicelli, M. Andreani, I. Dugail, and B. Feve In Vitro Suppression of the Lipogenic Pathway by the Nonnucleoside Reverse Transcriptase Inhibitor Efavirenz in 3T3 and Human Preadipocytes or Adipocytes J. Biol. Chem., April 9, 2004; 279(15): 15130 - 15141. [Abstract] [Full Text] [PDF]

				K. E. Yarasheski, P. Tebas, S. Claxton, D. Marin, T. Coleman, W. G. Powderly, and C. F. Semenkovich Visceral adiposity, C-peptide levels, and low lipase activities predict HIV-dyslipidemia Am J Physiol Endocrinol Metab, October 1, 2003; 285(4): E899 - E905. [Abstract] [Full Text] [PDF]

				C. Cammalleri and R. J. Germinario The effects of protease inhibitors on basal and insulin-stimulated lipid metabolism, insulin binding, and signaling J. Lipid Res., January 1, 2003; 44(1): 103 - 108. [Abstract] [Full Text] [PDF]

				S. K. Gan, K. Samaras, C. H. Thompson, E. W. Kraegen, A. Carr, D. A. Cooper, and D. J. Chisholm Altered Myocellular and Abdominal Fat Partitioning Predict Disturbance in Insulin Action in HIV Protease Inhibitor-Related Lipodystrophy Diabetes, November 1, 2002; 51(11): 3163 - 3169. [Abstract] [Full Text] [PDF]

				S. Chavan, S. Kodoth, R. Pahwa, and S. Pahwa The HIV protease inhibitor Indinavir inhibits cell-cycle progression in vitro in lymphocytes of HIV-infected and uninfected individuals Blood, July 15, 2001; 98(2): 383 - 389. [Abstract] [Full Text] [PDF]

				M. Caron, M. Auclair, C. Vigouroux, M. Glorian, C. Forest, and J. Capeau The HIV Protease Inhibitor Indinavir Impairs Sterol Regulatory Element-Binding Protein-1 Intranuclear Localization, Inhibits Preadipocyte Differentiation, and Induces Insulin Resistance Diabetes, June 1, 2001; 50(6): 1378 - 1388. [Abstract] [Full Text]

				H. Murata, P. W. Hruz, and M. Mueckler The Mechanism of Insulin Resistance Caused by HIV Protease Inhibitor Therapy J. Biol. Chem., June 30, 2000; 275(27): 20251 - 20254. [Abstract] [Full Text] [PDF]

				P. Dowell, C. Flexner, P. O. Kwiterovich, and M. D. Lane Suppression of Preadipocyte Differentiation and Promotion of Adipocyte Death by HIV Protease Inhibitors J. Biol. Chem., December 22, 2000; 275(52): 41325 - 41332. [Abstract] [Full Text] [PDF]

				T. M. Riddle, D. G. Kuhel, L. A. Woollett, C. J. Fichtenbaum, and D. Y. Hui HIV Protease Inhibitor Induces Fatty Acid and Sterol Biosynthesis in Liver and Adipose Tissues Due to the Accumulation of Activated Sterol Regulatory Element-binding Proteins in the Nucleus J. Biol. Chem., September 28, 2001; 276(40): 37514 - 37519. [Abstract] [Full Text] [PDF]